Trial · NCT04866498
Pharmacotherapy Personalization of Cancer Patients
NCT04866498, Completed, Poznan University of Medical Sciences
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Pharmacotherapy Personalization of Cancer Patients. Trials, record NCT04866498. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04866498
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Pharmacotherapy Personalization of Cancer Patients
- NCT number
- NCT04866498
- Status
- Completed
- Enrollment
- 22 participants, actual
- Lead sponsor
- Poznan University of Medical Sciences
- Conditions
- Head and Neck Neoplasms, Oncologic Patients
- Interventions
- Infusion Intravenous
- First posted
- 2021-04-29
- Last updated
- 2021-04-29
Source ClinicalTrials.gov
Registered outcomes9
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Measurement of the depth of sedation using bispectral index | from the beginning of analgosedation to 6 hours after analgosedation | Continuous measurement of the depth of sedation using bispectral index during analgosedation in intensive care unit. |
| Secondary | Oxycodone plasma concentrations [ng/ml] | 3-4 times during infusion, 5, 10, 15, 30, 60 minutes and 2, 4, 6 hours after the infusion cessation | Measurements of oxycodone and noroxycodone plasma concentrations \[ng/ml\] during and after analgosedation. Whole blood samples (2.0 ml) were collected according to the study protocol. |
| Secondary | Dexmedetomidine plasma concentrations [ng/ml] | 3-4 times during infusion, 5, 10, 15, 30, 60 minutes and 2, 4, 6 hours after the infusion cessation | Measurements of dexmedetomidine plasma concentrations \[ng/ml\] during and after analgosedation. Whole blood samples (2.0 ml) were collected according to the study protocol. |
| Secondary | Midazolam plasma concentrations [ng/ml] | 3-4 times during infusion, 5, 10, 15, 30, 60 minutes and 2, 4, 6 hours after the infusion cessation | Measurements of midazolam and alfa-hydroxymidazolam plasma concentrations \[ng/ml\] during and after analgosedation. Whole blood samples (2.0 ml) were collected according to the study protocol. |
| Secondary | Propofol plasma concentrations [ng/ml] | 3-4 times during infusion, 5, 10, 15, 30, 60 minutes and 2, 4, 6 hours after the infusion cessation | Measurements of propofol plasma concentrations \[ng/ml\] during and after analgosedation. Whole blood samples (2.0 ml) were collected according to the study protocol. |
| Secondary | Systolic blood pressure | before the beginning of analgosedation, during analgosedation, up to 6 hours after analgosedation | Measurements of systolic blood pressure during analgosedation in intensive care unit. |
| Secondary | Diastolic blood pressure | before the beginning of analgosedation, during analgosedation, up to 6 hours after analgosedation | Measurements of diastolic blood pressure during analgosedation in intensive care unit. |
| Secondary | Heart rate | before the beginning of analgosedation, during analgosedation, up to 6 hours after analgosedation | Measurements of heart rate during analgosedation in intensive care unit. |
| Secondary | Mean arterial pressure | before the beginning of analgosedation, during analgosedation, up to 6 hours after analgosedation | Measurements of mean arterial pressure during analgosedation in intensive care unit. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT04866498
GET https://conductscience.org/api/trials/v1/NCT04866498/registered